Company news
Dianthus Therapeutics, Inc. news in 2022
Dianthus Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial
December 19, 2022
Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial
December 11, 2022
Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates
December 11, 2022
Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting
November 2, 2022
Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference
October 31, 2022
Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors
August 16, 2022
Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights
August 3, 2022
Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference
August 1, 2022
Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights
May 15, 2022
Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway
April 13, 2022
Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare Conference
March 2, 2022
Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022
January 9, 2022
Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology Conference
January 4, 2022
Decks in 2022
- Magenta Therapeutics — ASH Annual Meeting 2022
Conference · 31 slides · Dec 13, 2022